Skip to content

Trial Summary

A Phase 2, Open-label, Multicentre, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patient With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy

Acronym:

ARTISTRY-6

ACTRN/NCT /ethics:

NCT04830124

Scientific title:

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma – ARTISTRY-6

Sponsor / Cooperative group:

Alkermes, Inc.

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Advanced
Anticipated Start Date2021-05-27
Anticipated End Date2025-09-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6410
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting